In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s shares closed yesterday at $232.29.
According to TipRanks, Matson is an analyst with an average return of -1.0% and a 43.99% success rate. Matson covers the Healthcare sector, focusing on stocks such as Conmed, Medtronic, and Teleflex.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $250.71 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $274.02 and a one-year low of $189.05. Currently, Resmed has an average volume of 474.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).
Read More on RMD:
- ResMed upgraded to Buy from Neutral at BofA
- ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
- ResMed initiated with a Hold at Jefferies
- ResMed Announces Participation in the Bank of America Global Healthcare Conference
- ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference
